Document:

EX-10.1

 Exhibit 10.1 
  

 
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

THIS AGREEMENT is made and effective as of February 24, 2022 (the “Effective Date”). 

BETWEEN: 
 Dr. Christopher
Astle, having a residence at [...***...]1 
 (the
“Employee”) 
 AND: 
 ZYMEWORKS
INC., a corporation registered in the Province of British Columbia and having its principal place of business at 800-114 East 4th Avenue, Vancouver, BC,
V5T 1G4, Canada 
 (the “Company”) 

WHEREAS 
 A. The Company is a clinical-stage biopharmaceutical
company dedicated to the development of next-generation multifunctional biotherapeutics; 
 B. The Employee has worked for the Company since April 1,
2021 (the “Start Date”), pursuant to an Employment Agreement dated effective April 1, 2021 (the “Initial Employment Agreement”); 

C. In consideration of the Employee’s continued commitment to the Company and the Company increasing the compensation payable to the Employee as stated in
Article 3 and Article 4 herein, the Company and the Employee have agreed to amend and restate the terms and conditions of the Initial Employment Agreement as provided herein and have this Amended and Restated Employment Agreement
(“Agreement”) supersede and replace all previous employment agreements and related amendments as of the Effective Date. 
 NOW THEREFORE THIS
AGREEMENT WITNESSES that for and in consideration of the promises and mutual covenants and agreements hereinafter contained, the parties hereto covenant and agree as follows: 

 

	1 	 Personal Information – Contact Information. 

 

 
  

 ARTICLE 1 – GENERAL 

1.1 Definitions. Unless otherwise defined, all capitalized terms used in this Agreement will have the meanings given below: 

 

	 	(a)	 “Business” means the business of researching, developing and commercializing therapeutic proteins,
antibodies, and any other research, development and manufacturing work considered, planned or undertaken by the Company during the Employee’s employment; 

 

	 	(b)	 “Confidential Information” means trade secrets and other information, in whatever form or media, in
the possession or control of the Company, which is owned by the Company or by one of its clients or suppliers or a third party with whom the Company has a business relationship (collectively, the “Associates”), and which is not generally
known to the public and has been specifically identified as confidential or proprietary by the Company, or its nature is such that it would generally be considered confidential in the industry in which the Company or its Associates operate, or which
the Company is obligated to treat as confidential or proprietary. Confidential Information includes, without limitation, the following: 

  

	 	(i)	 the products and confidential or proprietary facts, data, techniques, materials and other information related
to the business of the Company, including all related development or experimental work or research, related documentation owned or marketed by the Company and related formulas, algorithms, patent applications, concepts, designs, flowcharts, ideas,
programming techniques, specifications and software programs (including source code listings), methods, processes, inventions, sources, drawings, computer models, prototypes and patterns; 

 

	 	(ii)	 information regarding the Company’s business operations, methods and practices, including corporate
strategy, market research, market strategies, marketing plans, public relations strategies, product pricing and strategies, advertising sources, lists and information concerning current and prospective customers, billing information, suppliers,
packaging, merchandizing, distribution, methods of production, manufacturing, pending projects or proposals, margins and hourly rates for staff and information regarding the financial, legal and corporate affairs of the Company, including business
plans and projections and information regarding the Company’s financial condition, operations, assets and liabilities, financial data, business structures, business ventures, existing or contemplated businesses, products, or services;

  

	 	(iii)	 employee information, contacts, and wage information (other than Employee’s own); and

 

 
  

	 	(iv)	 technical and business information of, or regarding, the Company’s Associates. 

The above list is not exhaustive, and Confidential Information also includes other information that is marked or otherwise identified as
confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is known or used; 

 

	 	(c)	 “Developments” means all inventions, ideas, concepts, designs, improvements, discoveries,
modifications, computer software, and other results which are or have been conceived of, developed by, written, or reduced to practice by the Employee, alone or jointly with others (including, where applicable, all modifications, derivatives,
progeny, models, specifications, source code, design documents, creations, scripts, artwork, text, graphics, photos and pictures) at any time; 

  

	 	(d)	 “Excluded Developments” means any Development that meets the following requirements:

 an invention for which no equipment, supplies, facility, or Confidential Information of the employer was used and
which was developed entirely on the employee’s own time, unless 
 (i) the invention relates (A) directly to the business
of the employer, or (B) to the employer’s actual or demonstrably anticipated research or development, or 
 (ii) the
invention results from any work performed by the employee for the employer. 
  

	 	(e)	 “Prior Developments” means any Development that the Employee establishes was developed prior to the
Employee performing such services for the Company and precedes the Employee’s initial engagement with the Company. 

 1.2
Sections and Headings. The division of this Agreement into Articles and Sections and the insertion of headings are for the convenience of reference only and do not affect the construction or interpretation of this
Agreement. The terms “hereof”, “hereunder” and similar expressions refer to this Agreement and not to any particular Article, Section or other portion hereof and include any agreement supplemental hereto. Unless something in
the subject matter or context is inconsistent therewith, references herein to Articles and Sections are to Articles and Sections of this Agreement. 

 

 
  

 ARTICLE 2– EMPLOYMENT 

2.1 Services. 
 On the Effective Date, the Employee will
continue employment with the Company in the position of Senior Vice President and Chief Financial Officer on the terms and conditions set out in this Agreement. For the purpose of calculating any entitlements pursuant to this Agreement based on
length of service, the Company will use the Start Date for all such calculations. 
 2.2 Qualifications. 

 

	 	(a)	 The Employee acknowledges that the falsification or misrepresentation of qualifications, including but not
limited to education, skills, prior experience, depth and/or breadth of knowledge, references or similar matters, used to secure the position of Senior Vice President and Chief Financial Officer, represents a breach of this contract.

  

	 	(b)	 Employment Duties. Subject to the direction and control of the senior management of the Company
(“Management”), the Employee will perform the duties set out in Appendix “A” to this Agreement and any other duties that may be reasonably assigned to him/her by Management from time to time. Management may alter the duties
Employee is expected to perform for the Company at any time with or without notice. 

 2.3 Throughout the term of this Agreement, the
Employee will: 
  

	 	(a)	 diligently, honestly and faithfully serve the Company and will use all reasonable efforts to promote and
advance the interests and goodwill of the Company; 

  

	 	(b)	 devote him/herself in a full-time capacity to the business and affairs of the Company; 

 

	 	(c)	 adhere to all applicable policies and procedures of the Company as in effect and as amended from time to time,
including but not limited to the Company’s Code of Business Conduct and Ethics; 

  

	 	(d)	 exercise the degree, diligence and skill that a reasonably prudent Senior Vice President and Chief Financial
Officer would exercise in comparable circumstances; 

  

	 	(e)	 refrain from engaging in any activity which will in any manner, directly or indirectly, compete with the trade
or business of the Company except in accordance with Sections 2.4 and 2.6 herein and as outlined under the Conflict of Interest guidelines in the Company’s corporate policies and procedures as in effect and as amended from time to time;
and 

 

 
  

	 	(f)	 not acquire, directly or indirectly, any interest that constitutes 5% or more of the voting rights attached to
the outstanding shares of any corporation or 5% or more of the equity or assets in any firm, partnership or association, the business and operations of which in any manner, directly or indirectly, compete with the trade or business of the Company.

 2.4 The Employee will disclose to Management all potential conflicts of interest and activities which could reasonably be seen to
compete, indirectly or directly, with the trade or business of the Company. Management will determine, in its sole discretion, whether the activity in question constitutes a conflict of interest or competition with the Company. To the extent that
Management, acting reasonably, determines a conflict of interest or competition exists, the Employee will discontinue such activity forthwith or within such longer period as Management agrees. The Employee will immediately certify in writing to the
Company that he/she has discontinued such activity and that he/she has, as required by Management, cancelled any contracts or sold or otherwise disposed of any interest or assets over the 5% threshold described in Section 2.3(f) herein acquired
by the Employee by virtue of engaging in the impugned activity, or where no market exists to enable such sale or disposition, by transfer of the Employee’s beneficial interest into blind trust or other fiduciary arrangements over which the
Employee has no control or direction, or other action that is acceptable to the Board. 
 2.5 The Employee will not be employed by another company or provide
consulting or other services to other companies or commercial entities while employed by the Company, without the expressed written permission of the Company. By seeking and accepting employment with the Company, the Employee recognizes that the
Employee is employed by the Company for the expressed benefit of advancing the scientific, development and business objectives of the Company and that concurrent employment outside the Company may detract from those objectives. 

2.6 Notwithstanding Sections 2.3, 2.4 and 6.4, the Employee is not restricted from nor is required to obtain the consent of the Company to make
investments in any company which is involved in pharmaceuticals or biotechnology with securities listed for trading on any Canadian or U.S. stock exchange, quotation system or the
over-the-counter market. 
 2.7 For the purposes of Sections 2.3 2.4 and
2.6 herein, “Employee” includes any entity or company owned or controlled by the Employee. 
 ARTICLE 3 – COMPENSATION 

3.1 Base Salary. As compensation for all services rendered under this Agreement, the Company will pay to the Employee and the Employee will accept from
the Company a base salary at the rate of $375,000 (USD) per annum. The base salary will be paid semi-monthly, in equal instalments, less statutory and other authorized deductions. 

 

 
  

 3.2 Stock Options. The Employee shall be granted 125,000 options to acquire shares of common stock of
the Company (the “Shares”), provided the Employee is employed by the Company on the grant date (the “Options”). The exercise price of the Options will be set in accordance with the terms of the Company’s Amended and Restated
Stock Option and Equity Compensation Plan, or such other relevant plan as may be in effect on the grant date (the “Equity Compensation Plan”), and the Options will vest and become exercisable in accordance with the terms of such Equity
Compensation Plan. A copy of the Equity Compensation Plan in effect as of the Effective Date is attached hereto as Appendix “B”. 
 3.3
Incentive Plans. The Employee shall be entitled to participate in certain incentive programs for the Company’s Employees, including, without limiting the generality of the foregoing, share option plans, share purchase plans,
profit-sharing or bonus plans (including target annual bonus as described in Section 3.4) (collectively, the “Incentive Plans”). Such participation shall be on the terms and conditions of such Incentive Plans as at the date hereof or
as may from time to time be amended or implemented by the Company in its sole discretion. A copy of the Company’s Amended and Restated Employee Stock Purchase Plan in effect as of the Effective Date is attached hereto as Appendix “C”.

 3.4 Target Annual Bonus. Subject to Management discretion based on factors including Company performance, the Employee will be eligible to earn an
annual bonus, with an initial target amount of 35% of base salary. The Employee will be eligible to receive up to a full (non-prorated bonus) if the Effective Date is on or prior to June 30 of the year of
the Effective Date. The Employee will be eligible to receive a prorated bonus if the Effective Date is on or after July 1 of the year of the Effective Date. 

3.5 Performance and Salary Review. Management will review the Employee’s performance, base salary, and equity participation level under the terms
of any Incentive Plans annually beginning in December 2022, or as otherwise approved by the Compensation Committee, with interim reviews, coaching and feedback throughout the year to support the Employee in his/her career development objectives and
the achievement of personal, departmental and corporate goals. The timing of performance and salary reviews may from time to time be amended by the Company in its sole discretion. 

3.6 Expenses. The Company will reimburse the Employee for all ordinary and necessary expenses incurred by the Employee in the performance of the
Employee’s duties under this Agreement. Reimbursement of such expenses will be made in accordance with the Company’s policies. 
 3.7
Professional Fees. The Company will reimburse the Employee for annual registration and/or licensing fees required to maintain the Employee’s status as a member in good standing with the appropriate professional bodies required to
continue effective employment, and which were held by the Employee as of the Start Date. The Company will reimburse reasonable costs incurred by the Employee to complete the minimum annual continuing professional development requirements required to
maintain such status. 

 

 
  

 3.8 Vacation. The Employee will be eligible for twenty (20) days’ paid vacation per calendar
year, earned pro rata at a rate of 1.66 days per completed month of service. In accordance with the Company’s People policies, vacation time in excess of ten (10) days not taken during the year in which it is earned may not be carried
forward into the subsequent year without the written pre-approval of Management. Unused vacation time will not be paid out at the end of the fiscal year. Upon termination, vacation not taken in the calendar
year will be paid out according to the Employees’ annual salary rate prorated to the number of days’ vacation not taken. 
 3.9 Benefits.
The Employee will be eligible to participate in all benefit plans generally available to Employees of the Company, subject to meeting applicable eligibility requirements of such plans. 

3.10 Sick Leave. The Employee will be entitled to take up to ten (10) days paid sick leave per calendar year, earned pro rata at a rate of 0.83
days per completed month of service. Unused sick days will not be paid out or carried forward into the subsequent year. 
 ARTICLE 4 – TERM AND
TERMINATION 
 4.1 Term. This Agreement will commence on the Effective Date and will terminate on the effective date of termination by either the
Employee or the Company in accordance with Section 4.2 of this Agreement. 
 4.2 Termination. 

(a) Termination for Cause. The Company may terminate the employment of the Employee for cause at any time, without notice, damages or
compensation of any kind. 
  

	 	(b)	 Termination Without Cause. The Company may terminate the employment of the Employee without cause at any
time by providing the Employee with: 

  

	 	(i)	 written notice or payment in lieu of notice to the Employee as follows: 

 

	 	A.	 twelve (12) months of notice or the equivalent of twelve (12) months of base salary as of the date
notice is given, or any combination thereof that totals twelve (12) months of combined notice and base salary, if termination of employment occurs during the first three years of employment measured from the Start Date (with any base salary
equivalent payable over twelve (12) months, or sooner, at the sole discretion of the Company, subject to the requirements to pay termination under applicable employment standards legislation); and 

 

 
  

	 	B.	 commencing in the fourth year of employment measured from the Start Date, an additional one (1) month of
notice or the equivalent of one (1) month of base salary as of the date notice is given, or any combination thereof, for each additional completed year of service, up to a total maximum of eighteen (18) months (payable over eighteen
(18) months, or sooner, at the sole discretion of the Company, subject to the requirements to pay termination pay under applicable employment standards legislation); and 

 

	 	(ii)	 continuation of group extended health and dental benefits through the applicable notice period stated in
Section 4.2(b) herein (where all other benefits terminate on the last day worked by the Employee). 

  

	 	(c)	 Resignation. The Employee may terminate his/her employment with the Company by giving prior written
notice to Management of not less than thirty (30) days or such shorter period as the Employee and Management may agree. The Company may choose to waive all or part of the notice period and pay to the Employee the base salary to be earned during
the balance of the notice period instead. 

  

	 	(d)	 Termination following Change of Control. Notwithstanding any other provision in this Agreement, if
within twelve (12) months following a Change of Control of the Company (as defined below), the Employee’s employment is terminated by the Company without cause, the Employee shall receive as severance eighteen (18) months of base
salary and group extended health and dental benefits continuation as of the date of termination (with the severance payable over eighteen (18) months, or sooner, at the sole discretion of the Company, subject to the requirements to pay
termination pay under applicable employment standards legislation), and full vesting acceleration of all unvested stock options or other equity grants made to the Employee as of the date of termination. For all purposes of this Agreement,
“Change of Control” means: 

  

	 	(i)	 the acquisition, directly or indirectly, by any person or group of persons acting jointly or in concert, as
such terms are defined in the Securities Act, British Columbia, of common shares of the Company which, when added to all other common shares of the Company at the time held directly or indirectly by such person or persons acting jointly or in
concert constitutes for the first time in the aggregate 40% of more of the outstanding common shares of the Company and such shareholding exceeds the collective shareholding of the current directors of the Company, excluding any directors acting in
concert with the acquiring party; or 

 

 
  

	 	(ii)	 the removal, by extraordinary resolution of the shareholders of the Company, of more than 51% of the then
incumbent Board of the Company, or the election of a majority of Board members to the Company’s board who were not nominees of the Company’s incumbent board at the time immediately preceding such election; or 

 

	 	(iii)	 consummation of a sale of all or substantially all of the assets of the Company; or 

 

	 	(iv)	 the consummation of a reorganization, plan of arrangement, merger, or other transaction which has substantially
the same effect as to above. 

 Payment under Section 4.2(d) herein will be in lieu of and not in addition to payment
under Section 4.2(b). 
 4.3 Stock Options on Termination. Except as provided by Section 4.2(d), the vesting and exercise of any stock
options granted to the Employee in the event the Employee’s employment with the Company or this Agreement is terminated, for any reason, shall be governed by the terms of the Equity Compensation Plan and any applicable stock option agreement in
effect between the Company and the Employee at the time of termination. 
 4.4 Benefits Continuation and No Mitigation. The Employee shall not be
required to mitigate the amount of any payments provided for in this Section by seeking other employment or otherwise, nor shall the amount of any payment provided for in this Section be reduced by any compensation earned by the Employee as the
result of employment by another employer after the date of termination, or otherwise. Notwithstanding the forgoing, the Employee is required to report to the Company if he/she obtains replacement benefits coverage through new employment during any
period of group extended health and dental benefits continuation contemplated by this Article 4, and such benefits coverage by the Company will cease effective the date the Employee receives such new coverage and the Employee will not be entitled to
any payment in respect of such benefits coverage from the Company in respect of any notice period or severance payment contemplated in this Article 4. 
 4.5
No Additional Payments. Payment of severance, in accordance with Section 4.2(b) or Section 4.2(d) above, to the Employee by the Company will be full and adequate compensation to the Employee with respect to any claim relating to the
Employee’s employment or termination or manner of termination of the Employee’s employment, and the Employee waives any right that he/she may have to claim further payment, compensation or damages from the Company. 

4.6 Condition to Payment. Payment of any amount of severance under this Agreement in excess of any minimum required by the Employment Standards
Act is conditional upon execution by the Employee of a general release of all claims, satisfactory to the Company, in substantially the form appended to this Agreement as Appendix D. 

 

 
  

 4.7 Survival. Upon a termination of this Agreement for any reason, the Employee will continue to be
bound by the provisions of Article 4, Article 5, Article 6, Article 7, and Article 8. 
 ARTICLE 5 – CONFIDENTIALITY 

5.1 Confidential Information. 
  

	 	(a)	 Ownership of Confidential Information—The Employee acknowledges that the Confidential Information
is and will be the sole and exclusive property of the Company. The Company has a legitimate business interest in protecting its Confidential Information, including its trade secrets, as well as its substantial and ongoing customer, industry, and
employee relationships. The Employee acknowledges that the Employee has not, and will not, acquire any right, title or interest in or to any of the Confidential Information. 

 

	 	(b)	 Non-Disclosure, Use and Reproduction of Confidential
Information—The Company and its related entities, parents, subsidiaries, predecessors, successors, and affiliates, may provide and make available to the Employee certain Confidential Information regarding its business. This Confidential
Information is of substantial value and highly confidential, is not known to the general public, is the subject of the Company’s reasonable efforts to maintain its secrecy, includes professional and trade secrets, and is being provided and
disclosed to the Employee solely for use in connection with and during the Employee’s employment with the Company. The Employee will keep all the Confidential Information strictly confidential, and will not, either directly or indirectly,
either during or subsequent to employment with the Company, disclose, allow access to, transmit, transfer, use or reproduce any of the Confidential Information in any manner except as required to perform the duties of the Employee for the Company
and in accordance with all procedures established by the Company for the protection of the Confidential Information. Without limiting the foregoing, the Employee: 

 

	 	(i)	 will ensure that all the Confidential Information and all copies thereof, are clearly marked, or otherwise
identified as confidential to the Company and proprietary to the person or entity that first provided the Confidential Information, and are stored in a secure place while in the Employee’s possession, custody, charge or control;

  

	 	(ii)	 will not, either directly or indirectly, disclose, allow access to, transmit or transfer any of the
Confidential Information to any person other than to an employee, officer, or director of the Company but only upon a “need to know” basis for the benefit of the Company, without the prior written authorization of Management; and

 

 
  

	 	(iii)	 will not, except as required by the Employee’s position, use any of the Confidential Information to
create, maintain or market any product or service which is competitive with any product or service produced, marketed, licensed, sold or otherwise dealt in by the Company, or assist any other person to do so. 

 

	 	(c)	 Legally Required Disclosure—Notwithstanding the foregoing, to the extent the Employee is required
by law to disclose any Confidential Information, the Employee will be permitted to do so, provided that notice of this requirement is delivered to the Company in a timely manner, so that the Company may contest such potential disclosure.

  

	 	(d)	 Return of Materials, Equipment and Confidential Information—Upon request by the Company, and in any
event when the Employee leaves the employ of the Company, the Employee will immediately return to the Company all the Confidential Information and all other materials, computer programs, documents, memoranda, notes, papers, reports, lists, manuals,
specifications, designs, devices, drawings, notebooks, correspondence, equipment, keys, pass cards, and property, and all copies thereof, in any medium, in the Employee’s possession, charge, control or custody, which are owned by, or relate in
any way to the Business or affairs of the Company. 

  

	 	(e)	 Exceptions - The non-disclosure obligations of Employee under
this Agreement shall not apply to Confidential Information which the Employee can establish: 

  

	 	(i)	 is, or becomes, readily available to the public other than through a breach of this Agreement;

  

	 	(ii)	 is disclosed, lawfully and not in breach of any contractual or other legal obligation, to Employee by a third
party; or 

  

	 	(iii)	 through written records, was known to Employee, prior to the date of first disclosure of the Confidential
Information to Employee by the Company 

 5.2 Ownership of Developments 

 

	 	(a)	 Acknowledgment of Company Ownership—The Employee acknowledges that the Company will be the
exclusive owner of all the Developments made during the term of the Employee’s employment by the Company, except Excluded Developments, and to all intellectual property rights in and to such Developments. The Employee hereby assigns all right,
title and interest in and to such Developments and their associated intellectual property rights throughout the world and universe to the Company, including without limitation, all trade secrets, patent rights, copyrights, mask works, industrial
designs and any other intellectual property rights in and to each such Development, effective at the time each is created. Further, the Employee irrevocably waives all moral rights the Employee may have in such Developments. 

 

 
  

	 	(b)	 Excluded Developments and Prior Developments—The Company acknowledges that it will not own any
Excluded Developments or Prior Developments. 

  

	 	(c)	 Disclosure of Developments—To avoid any disputes over the ownership of Developments, the Employee
will provide the Company with a general written description of any of the Developments the Employee believes the Company does not own because they are Excluded Developments or Prior Developments. Thereafter, the Employee agrees to make full and
prompt disclosure to the Company of all Developments, including, without limitation, Excluded Developments, made during the term of the Employee’s employment with the Company. The Company will hold any information it receives regarding Excluded
Developments and Prior Developments in confidence. 

  

	 	(d)	 Further Acts—The Employee agrees to cooperate fully with the Company both during and after the
Employee’s employment by the Company, with respect to (i) signing further documents and doing such acts and other things reasonably requested by the Company to confirm the Company’s ownership of the Developments other than Excluded
Developments and Prior Developments, the transfer of ownership of such Developments to the Company, and the waiver of the Employee’s moral rights therein, and (ii) obtaining or enforcing patent, copyright, trade secret or other protection
for such Developments; provided that the Company pays all the Employee’s expenses in doing so, and reasonable compensation if such acts are required after the Employee leaves the employment by the Company. 

 

	 	(e)	 Employee-owned Inventions—The Employee hereby covenants and agrees with the Company that, unless
the Company agrees in writing otherwise, the Employee will not use or incorporate any Excluded Development or Prior Development in any work product, services, or other deliverables the Employee provides to the Company. If the Employee uses or
incorporates any Excluded Development or Prior Development with the Company’s permission, as provided above, the Employee (i) represents and warrants that he or she owns all proprietary interest in such Excluded Development or Prior
Development and (ii) grants to the Company, at no charge, a non-exclusive, irrevocable, perpetual, worldwide license to use, distribute, transmit, broadcast,
sub-license, produce, reproduce, perform, publish, practice, make, and modify such Excluded Development or Prior Development. 

 

 
  

	 	(f)	 Prior Employer Information—The Employee hereby covenants and agrees with the Company that during
the Employee’s employment by the Company, the Employee will not improperly use or disclose any confidential or proprietary information of any former employer, partner, principal, co-venturer, customer, or
independent contractor of the Employee and that the Employee will not bring onto the Company’s premises any unpublished documents or any property belonging to any such persons or entities unless such persons or entities have given their
consent. In addition, the Employee will not violate any non-disclosure, non-compete or proprietary rights agreement the Employee has signed with any person or entity
prior to the Employee’s execution of this Agreement, or knowingly infringe the intellectual property rights of any third party while employed by the Company. 

 

	 	(g)	 Protection of Computer Systems and Software—The Employee agrees to take all necessary precautions
to protect the computer systems and software of the Company, including, without limitation, complying with the obligations set out in the Company’s policies. 

5.3 Defend Trade Secrets Act. Pursuant to the Defend Trade Secrets Act of 2016, the Employee understands that: 

 

	 	(a)	 an individual may not be held criminally or civilly liable under any federal or state trade secret law for the
disclosure of a trade secret that: 

  

	 	(i)	 is made (A) in confidence to a federal, state, or local government official, either directly or
indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or 

  

	 	(ii)	 is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.

  

	 	(b)	 Further, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation
of law may disclose the employer’s trade secrets to the attorney and use the trade secret information in the court proceeding if the individual: 

  

	 	(i)	 files any document containing the trade secret under seal; and 

 

	 	(ii)	 does not disclose the trade secret, except pursuant to court order.

 

 
  

 ARTICLE 6 – RESTRICTIVE COVENANTS 

6.1 Non-solicitation by the Employee. The Employee agrees that at any time while employed by the Company and for
a period of one (1) year thereafter, the Employee will not, without the prior written consent of the Company induce or attempt to influence, directly or indirectly, an employee of the Company to leave the employ of the Company. 

6.2 Non-competition. The Employee agrees that while employed by the Company and for a period of six
(6) months thereafter, the Employee will not, without the prior written consent of the Company, directly or indirectly, anywhere in Canada or the United States, provide any professional services to any person or entity that can be reasonably
viewed as a competitor to the Business of the Company, while the Employee was employed by the Company, which relate to therapeutic antibody modeling, design, modification and commercialization for industrial and pharmaceutical applications. 

6.3 Reasonableness of Non-competition and Non-solicitation Obligations.
The Employee confirms that the obligations in Sections 6.1 and 6.2 are fair and reasonable given that, among other reasons: 
  

	 	(a)	 the sustained contact the Employee will have with the clients of the Company will expose the Employee to the
Confidential Information regarding the particular requirements of these clients and the Company’s unique methods of satisfying the needs of these clients, all of which the Employee agrees not to act upon to the detriment of the Company; and/or

  

	 	(b)	 the Employee will be performing important development work on the products or services owned, developed or
marketed by the Company; 

 and the Employee agrees that the obligations in Sections 6.1 and 6.2, together with the Employee’s
other obligations under this Agreement, are reasonably necessary for the protection of the Company’s good will, trade secrets and proprietary interests and that given the Employee’s general knowledge and experience they would not prevent
the Employee from being gainfully employed if the employment relationship between the Employee and the Company were to end. The Employee further confirms that the geographic scope of the obligation in Section 6.2 is reasonable given the nature
of the market for the products and business of the Company. The Employee also agrees that the obligations in Sections 6.1 and 6.2 are in addition to the confidentiality and non-disclosure obligations provided
for in this Agreement. 
 6.4 Conflict of Interest. The Employee recognizes that the Employee is employed by the Company in a position of
responsibility and trust and agrees that during the Employee’s employment with the Company, the Employee will not engage in any activity or otherwise put the Employee in a position which conflicts with the Company’s interests. Without
limiting this general statement, the Employee agrees that during the Employee’s employment with the Company, the Employee will not knowingly lend money to, guarantee the debts or obligations of or permit the name of the Employee or any part
thereof to be used or employed by any corporation or firm which directly or indirectly is engaged in or concerned with or interested in any Business in competition with the Business of the Company unless the Employee receives prior written
authorization from the Company. 

 

 
  

 6.5 Acknowledgments. The Employee acknowledges that as of the date of this Agreement: 

 

	 	(a)	 a breach of this Agreement would cause the Company irreparable harm and as a result the Employee consents to
the issuance of an injunction or other appropriate remedy required to enforce the covenants contained herein; 

  

	 	(b)	 in the event the Employee breaches any covenant contained herein, the one (1) year period provided for in
Sections 6.1 and the six (6) month period provided for in Section 6.2 will be extended for a period of three (3) months from the date any such breach is cured; and 

 

	 	(c)	 in the event it is necessary for the either party to retain legal counsel to enforce any of the terms and
conditions of this Agreement, the prevailing party will pay the other parties’ reasonable legal fees, court costs and other related expenses. 

ARTICLE 7 – ENFORCEMENT 
 7.1 Application to
the British Columbia Supreme Court or the Federal Court of Canada. In the event of a breach or threatened breach by the Employee of any of the provisions of Article 5 or Article 6, the Company will be entitled to injunctive relief
restraining the Employee from breaching such provisions, as set forth in this Agreement. Nothing in this Agreement precludes the Company from obtaining, protecting or enforcing its intellectual property rights, or enforcing the Employee’s
fiduciary, non-competition, non-solicitation, confidentiality or any other post-employment obligations in a court of competent jurisdiction, or from pursuing any other
remedy available to it for such breach or threatened breach, including the recovery of damages from the Employee. 
 7.2 Severability and Limitation.
All agreements and covenants contained herein are severable and, in the event any of them will be held to be invalid by any competent court, this Agreement will be interpreted as if such invalid agreements or covenants were not contained herein.
Should any court or other legally constituted authority determine that for any such agreement or covenant to be effective that it must be modified to limit its duration or scope, the parties hereto will consider such agreement or covenant to be
amended or modified with respect to duration and scope so as to comply with the orders of any such court or other legally constituted authority or to be enforceable under the laws of the Province of British Columbia, and as to all other portions of
such agreement or covenants they will remain in full force and effect as originally written. 

 

 
  

 ARTICLE 8 – MEDIATION/ARBITRATION 

8.1 Mediation/Arbitration. In the event of a dispute hereunder which does not involve the Company seeking a court injunction or remedy pursuant to
Article 7, such dispute shall be mediated and, if necessary, arbitrated pursuant to the terms of this Article (the “Med/Arb Agreement”). 
 8.2 The
parties will work in good faith and in confidence to resolve any disputes that arise in connection with this Agreement. The parties agree to conduct in good faith at least two meetings (the “Meetings”) to seek resolution to a dispute
before delivering a notice to mediate. 
 8.3 Where a dispute arises out of or in connection with this Agreement that cannot be resolved by the parties
through the Meetings, the parties agree to seek a confidential settlement of such dispute by mediation followed, if necessary, by arbitration. 
 8.4 At any
time after a dispute has been raised and no resolution has been achieved through the Meetings, either party may give written notice to the other party requesting mediation of the dispute (the “Mediation Notice”) by a single mediator. If
the parties cannot agree on a mediator within fourteen (14) days after delivery of the Mediation Notice, then either party may make application to the British Columbia Mediator Roster Society to appoint one. The mediation will be held in
Vancouver, British Columbia and the costs of mediation will be shared equally between the parties. 
 8.5 If the parties are unable to reach a mediated
settlement within 120 days after delivery of the Mediation Notice, either of the parties may submit the dispute to binding arbitration by giving written notice to the other party and the mediator requesting arbitration of the dispute (the
“Arbitration Notice”) by a single arbitrator (the “Arbitrator”). Within fourteen (14) days of the delivery of the Arbitration Notice, the parties will select the Arbitrator. In the event the parties do not agree on an
arbitrator, either party may apply to the BC Supreme Court to have one appointed. With input from the parties, the Arbitrator will determine and notify the parties of the rules of and timetable for arbitration. The Arbitrator will hear the
submissions of the parties in accordance with such procedures as he or she may establish, and shall use reasonable best efforts to render a decision within sixty (60) days after the date of receiving or hearing the parties’ final
submissions. The decision of the Arbitrator shall be final and binding on the parties involved in the dispute and shall not be subject to appeal. The arbitration will be held in Vancouver, British Columbia, and the costs of arbitration will be
shared equally between the parties. 
 8.6 Nothing in this Med/Arb Agreement precludes the Company from obtaining, protecting or enforcing its intellectual
property rights, or enforcing the Employee’s fiduciary, non-competition, non-solicitation, confidentiality or any other post-employment obligations in a court of
competent jurisdiction, or from pursuing any other remedy available to it for such breach or threatened breach, including the recovery of damages from the Employee. 

 

 
  

 ARTICLE 9 – GENERAL 

9.1 Notices. Any notices to be given hereunder by either party to the other party may be effected in writing, either by personal delivery or by mail if
sent certified, postage prepaid, with return receipt requested. Mailed notices will be addressed to the parties at the address set out on the first page of this Agreement, or as otherwise specified from time to time. Notice will be effective upon
delivery. 
 9.2 Independent Legal Advice. The Employee specifically confirms that he/she has been advised to retain his/her own independent legal
advice prior to entering into this Agreement. 
 9.3 Construction. The parties acknowledge that each party and its respective counsel have had the
opportunity to independently review and negotiate the terms and conditions of this Agreement, and that the normal rule of construction to the effect that any ambiguities are to be construed against the drafting party will not be employed in the
interpretation of this Agreement or any exhibits or amendments hereto. 
 9.4 Assignment. The Employee cannot assign his/her interest in this
Agreement. 
 9.5 Benefit of Agreement. This Agreement will inure to the benefit of and be binding upon the respective heirs, executors,
administrators, successors and permitted assigns of the parties hereto. 
 9.6 Entire Agreement. The Appendices to this Agreement, together with the
terms and conditions contained within this Agreement constitute the entire agreement between the parties hereto with respect to the subject matter hereof and cancels and supersedes any prior employment agreements, understandings and arrangements
between the parties hereto with respect thereto, including the Initial Employment Agreement. There are no representations, warranties, terms, conditions, undertakings or collateral agreements, express, implied or statutory, between the parties other
than as expressly set forth in this Agreement. 
 9.7 Amendments and Waivers. No amendment to this Agreement will be valid or binding unless set forth
in writing and duly executed by the Employee and the Chief People Officer of the Company or his/her designee. No waiver of any breach of any provision of this Agreement will be effective or binding unless made in writing and signed by the party
purporting to give the same and, unless otherwise provided in the written waiver, will be limited to the specific breach waived. 
 9.8 Governing Law.
This Agreement will be governed by and construed, enforced and interpreted exclusively in accordance with the laws of the Province of British Columbia and the applicable laws of Canada therein, except as specified in Articles 5.3 and 8 above. 

 

 
  

 IN WITNESS WHEREOF the parties have executed this Agreement as of the date first above written. 

 

			
	ZYMEWORKS INC.
		
	By:	 	 /s/ Neil Klompas

		 	Neil Klompas, Chief Operating Officer

  

	
	 SIGNED AND DELIVERED
 by Employee:

 
 /s/ Christopher Astle

Signature
  

February 24, 2022
 DateExhibit 10.1

 

Research
Agreement

 

 

This Research Agreement (the “Agreement”)
is effective on the date of the last authorized signature below (the "Effective Date"), between Sunshine Biopharma, Inc. (“Sponsor”),
with offices located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, H9R 0A5, Canada, and the Arizona Board
of Regents on behalf of the University of Arizona, an Arizona body corporate ("University"), with offices located at University
Services Building Room 510, 888 N. Euclid Ave., Tucson, Arizona 85719.

 

	☒	If checked, this Agreement is also subject to additional terms and conditions set forth in the attached Exhibit C. In the event of a conflict between any specific terms or conditions in this Agreement and Exhibit C, Exhibit C shall govern.

 

 

The parties hereby agree as follows:

 

		1.	Scope of Work and Payment

 

		1.1	Research Project. The University will use reasonable efforts to perform the research project as
described in the Statement of Work (the “SOW”) incorporated herein by reference as “Exhibit A: Research Project Statement
of Work dated November 15, 2021” (the “Research Project”), in consideration for Sponsor making the payments in accordance
with the milestones (the “Milestones”) specified in the SOW as described in Exhibit B (the “Costs of Research”).
Unless otherwise set forth on Exhibit B, payments will be due within 30 days of the date of the University’s invoice. The Research
Project will be supervised by Gregory Thatcher, Ph.D., employed by University (the “Principal Investigator”).

 

		1.2	Reports. During the Term of this Agreement, the University shall provide the Sponsor with brief
bi-weekly email reports outlining the work performed to date, the results obtained and planned next steps (the “Reports”).
Such Reports shall be used by the University and Sponsor to make decisions in respect of the Milestones and make adjustments to the SOW,
if necessary. A final report shall be in the form of manuscript for a publication to be co-authored by University and Sponsor scientists
and prepared by the University within sixty (60) days following completion of the Research Project (the “Final Report”).

 

		1.3	Non-Exclusivity of Research. Both parties acknowledge and agree that each party may engage in other
research that is similar to the Research Project but not involving the same compounds of the Research Project, funded by public or private
sources and conducted separately, and the other party has no rights or obligations with respect to such separate research.

 

		1.4	Equipment and Supplies. Equipment and supplies purchased specifically to conduct the Research Project
belong to University at the termination of this Agreement.

 

		2.	Term and Termination

 

		2.1	Term. This Agreement begins on the Effective Date and will expire upon completion of the work specified
in the SOW and delivery of the Final Report to Sponsor(the “Term”), unless sooner terminated in accordance with the provisions
of this Section 2.

 

		2.2	Termination for Convenience. Either party may terminate this Agreement at any time upon ninety
(90) days written notice to the other party. Sponsor may terminate this Agreement at any time upon thirty (30) days written notice to
the University if it determines that the research results do not favorably support the development of a commercially viable drug based
on the science of the Research Project.

 

 

 

    	 	1	 

     

    

 

		2.3	Termination for Breach. Either party may terminate this Agreement in the event the other party
commits a material breach of any of the terms or conditions of this Agreement, and fails to remedy such breach within thirty (30) days
after receipt of written notice from the other party. The right to terminate for material breach is in addition to any other remedies
which a party may have at law or in equity.2.4Effect of Termination. Upon any expiration or termination of this Agreement,
University will work to close down the Research Project, including termination of any obligations in force (except those that are non-cancelable),
and will notify Sponsor of those obligations remaining as of the date of termination. Sponsor will pay University all Costs of Research
incurred by University up to the date of termination. Further, if Sponsor terminates for its convenience or if University terminates for
Sponsor’s material breach, Sponsor will reimburse University for all costs associated with termination. Termination or expiration
of this Agreement will not affect the rights and obligations of the parties that have accrued prior to the termination date, including
non-cancellable commitments, and specifically the obligations set forth in Sections headed Confidentiality Obligations, Indemnification
and Limitation of Liability and General Provisions will survive termination or expiration. If Sponsor terminates this Agreement prior
to completion of the Research Project or if University terminates for material breach by Sponsor, the Intellectual Property rights set
forth in the Section headed Intellectual Property will terminate; otherwise these rights will survive expiration of the Agreement.

 

		3.	Research Results 

 

Sponsor and University agree that,
in exchange for paying the Costs of Research, Sponsor may use the results of the research (“Research Results”) for any purpose,
but may not publish Research Results prior to Principal Investigator’s publication of Research Results. The University retains ownership
of the Research Results, and the right to publish as set forth in Section 5. Any Research Result that also constitutes Intellectual Property
as set forth in Section 4.1 below is considered Intellectual Property, and is subject to the terms set forth in Section 4 below.

 

		4.	Intellectual Property

 

		4.1	Ownership of Intellectual Property. The parties acknowledge that inventions, discoveries, and other
technology that is patentable, or that is copyrightable software (“Intellectual Property”) may arise from the Research Project.
University owns all Intellectual Property invented or authored by University personnel under the Research Project (“University Intellectual
Property”). The parties will jointly own all Intellectual Property invented or authored jointly by University personnel and Sponsor
personnel under the Research Project (“Joint Intellectual Property”). Inventorship and authorship will be determined in accordance
with United States intellectual property laws. This Agreement does not grant either party any rights to any pre-existing Intellectual
Property or to any Intellectual Property developed outside the scope of the Research Project.

 

		4.2	Disclosure and Filing. All Intellectual Property arising from University’s performance of
the Research Project will be disclosed to University’s tech transfer organization, Tech Launch Arizona, who will promptly provide
Sponsor with a confidential written disclosure of the Intellectual Property. The University may file for patent or other protection for
University Intellectual Property at its discretion, or at the request of the Sponsor. Sponsor will reimburse University for fees and expenses
associated with patent prosecution or other protection if such actions are taken at Sponsor request, or if Sponsor seeks a license under
Section 4.3. University will control patent prosecution on any University Intellectual Property. If Sponsor is reimbursing University,
the parties will collaborate during the patent prosecution process, and the University will consider all of Sponsor’s input in good
faith.

 

		4.3	License to Intellectual Property. The University grants to Sponsor a non-exclusive right to use
the University Intellectual Property for internal research purposes. The University also grants to Sponsor the first option to negotiate
for a commercial, royalty-bearing license .under University Intellectual Property and University’s rights in Joint Intellectual
Property within the field of use and territory to be mutually agreed by the parties. Sponsor may exercise this option by submitting a
request in writing to University, and the parties will negotiate such license arrangement in good faith and on commercially reasonable
terms. The option must be exercised in writing within three (3) months after completion of the Research Project and delivery of final
report to Sponsor as specified in Section 2.1 (“Option Period”). If Sponsor fails to exercise the option within the Option
Period, or if the parties do not reasonably agree on terms for a license within three (3) months after the date the Sponsor exercises
the option, the University will have no further obligation to Sponsor with respect to a commercial license to that Intellectual Property.

 

 

 

    	 	2	 

     

    

 

		4.4	Retained Rights. Without limiting any other rights it may have and even if Sponsor exercises its
option as set forth in Section 4.3 above, the University specifically reserves the right in and to the University Intellectual Property
and Joint Intellectual Property for any research, public service, and/or educational purposes, and to grant licenses to other academic
institutions for these same reserved rights.

 

		5.	Publication 

 

Notwithstanding anything to the contrary
in this Agreement, the University and its employees have the right, at their discretion, to release information or to publish any data,
writings, or material resulting from the Research Project, including Research Results and Intellectual Property, and to use it in any
way for its educational and research purposes.  The University will furnish the Sponsor with a copy of any proposed publication in
advance of the proposed publication date and grant the Sponsor thirty (30) days for review and comment. Within this period, the Sponsor
may request the University, in writing, to delay such publication for a maximum of an additional (60) days in order to protect the potential
patentability of any invention described therein. Such delay will not, however, be imposed on the filing of any student thesis or dissertation.
Sponsor’s failure to object to a publication or presentation within the thirty (30) day period above will be deemed acceptance by
Sponsor.

 

		6.	Public Statements; Use of Names and Logos

 

		6.1	No Use of Names or Logos. Neither party is permitted to use the names, logos, or other identifiers
associated with the other party without such party’s express prior written consent in each instance.

 

		6.2	Press Releases. Except as required by law, neither party will issue any press release or other
public statements in connection with this Agreement or the Research Project without the other party’s prior written consent. University
will acknowledge Sponsor’s support of the Research Project in scientific publications and communications. All statements by the
parties will accurately describe the scope and nature of their participation. University may, without prior consent from Sponsor, list
Research Project title, amount awarded, Sponsor name, and Principal Investigator(s) names and department(s) affiliation(s) in its reports,
which while not disseminated, are available to the public.

 

		6.3	No University Endorsements. In no event shall Sponsor (or its successors, employees, agents or
contractors) state or imply in any publication, advertisement, or other medium that the University approved or endorsed any product or
service. In no event shall the University’s performance of the Research Project be considered the basis for any endorsement of a
product or service.

 

		7.	Indemnification, Limitation of Liability, Limitation of Remedies, and Insurance

 

		7.1	Indemnification by Sponsor. Sponsor will indemnify, defend and hold harmless Principal Investigator
and University, its governing board, officers, agents, and employees, from any liability, loss or damage they may suffer as the result
of claims, demands, costs or judgments against them arising out of either party’s performance of the Research Project pursuant to
this Agreement, and/or Sponsor’s use of the University Intellectual Property, Joint Intellectual Property, Research Results, or
other information or materials provided under this Agreement, provided, however, that any such liability, loss, or damage resulting from
the following are excluded from this agreement to indemnify and hold harmless: (a) University’s failure to adhere to the terms of
the Research Project Statement of Work in all material respects; (b) University’s failure to comply with any applicable law or regulation;
or (c) negligence or willful misconduct in the performance of this Agreement by the Principal Investigator, University, or its board,
officers, agents, or employees as determined by a court of law. Principal Investigator and University agree to notify Sponsor promptly
of any such claim or action, and to cooperate with and to authorize Sponsor to carry out the sole management and defense of such claim
or action. Sponsor will not compromise or settle any claim or action without the prior written approval of each of the following if they
are a named party: Principal Investigator, University, its governing board, officers, agents, or employees.

 

 

 

    	 	3	 

     

    

 

		7.2	Disclaimer of Warranties and Limitation of Liability. SPONSOR ACKNOWLEDGES THAT THE WORK SET FORTH
IN THE RESEARCH PROJECT IS EXPERIMENTAL IN NATURE AND THAT UNIVERSITY MAKES NO WARRANTIES OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT, REGARDING THE RESEARCH PROJECT, RESEARCH RESULTS,
THE UNIVERSITY INTELLECTUAL PROPERTY, JOINT INTELLECTUAL PROPERTY, OR OTHER RESULTS PROVIDED BY THE UNIVERSITY UNDER THIS AGREEMENT.

 

		7.3	Limitation of Remedies. IN THE EVENT OF THE UNIVERSITY’S BREACH OR FAILURE TO PERFORM ANY
OBLIGATION UNDER THIS AGREEMENT, THE UNIVERSITY’S ENTIRE LIABILITY AND SPONSOR’S EXCLUSIVE REMEDY SHALL BE, AT THE UNIVERSITY’S
OPTION, EITHER (I) RETURN OF THE MONETARY CONSIDERATION PAID TO THE UNIVERSITY UNDER THIS AGREEMENT OR (II) THE UNIVERSITY’S PERFORMANCE
OF ANY OBLIGATION THAT FAILED TO SATISFY THE TERMS OF THIS AGREEMENT.

 

		7.4	Insurance. At all times during the Term, Sponsor shall obtain and keep in full force and effect,
general and professional liability insurance, including coverage for death, bodily or personal injury, and property damage, including
products liability, with limits of not less than $3,000,000 per each occurrence and $5,000,000 in the aggregate.

 

		8.	General Provisions 

 

		8.1	Applicable Law and Venue. This Agreement will be interpreted pursuant to the laws of the State
of Arizona, where the Research Project is performed. Any arbitration or litigation between the parties will be conducted in Pima County,
Arizona, and Sponsor hereby submits to venue and jurisdiction in Pima County, Arizona. This Agreement may be subject to mandatory non-binding
arbitration in accordance with applicable law.

 

		8.2	Non-Discrimination. The parties agree to be bound by state and federal laws and regulations governing
equal opportunity and non-discrimination and immigration.

 

		8.3	Conflict of Interest. This Agreement is subject to the provisions of A.R.S. 38-511. Within three
years from the Effective Date, the University may cancel this Agreement if any person significantly involved in negotiating, drafting,
securing or obtaining this Agreement for or on behalf of the University becomes an employee in any capacity of Sponsor or a consultant
to Sponsor with reference to the subject matter of this Agreement while the Agreement or any extension thereof is in effect.

 

		8.4	Notices. Notices will be in writing and deemed effective when sent, postage prepaid to:

 

If to Sponsor:

 

Sunshine Biopharma
Inc.

6500 Trans-Canada
Highway, 4th Floor

Pointe-Claire, Quebec
H9R 0A5

CANADA

 

If to
University (Notices and Correspondence):

UAHS Contracts

1670 E. Drachman
Street, 9th Floor

P.O. Box 210216

Tucson, Arizona
85721

 

 

 

    	 	4	 

     

    

 

		8.5	Entire Agreement; Modifications. This Agreement embodies the entire understanding of the parties
and supersedes any other agreement or understanding between the parties relating to the subject matter hereof. There are no additional
or supplemental agreements related to the subject matter hereof. No waiver, amendment or modification of this Agreement will be valid
or binding unless written and signed by the parties. Waiver by either party of any breach or default of any clause of this Agreement by
the other party will not operate as a waiver of any previous or future default or breach of the same or different clause of this Agreement.
In the event Sponsor issues a purchase order or instrument concerning the subject of this Agreement, the parties expressly agree that
the terms and conditions in such purchase order or instrument will have no force or effect.

 

		8.6	Export Laws. The parties acknowledge that this Agreement is subject to compliance with applicable
United States laws, regulations, or orders including those that may relate to the export of technical data and equipment, such as International
Traffic in Arms Regulations (“ITAR“) and/or Export Administration Act/Regulations (“EAR”), as may be amended,
and agree to comply with all such laws, regulations or orders. It is the intent of the parties not to disclose any export-controlled information.
However, if a party determines that export-controlled information must be disclosed, such party will provide the other party with written
notice containing the nature of the export-controlled information prior to any exchange of export-controlled information. Sponsor is solely
responsible for any violation of such laws and regulations involving Sponsor or its affiliates, and will defend, indemnify and hold harmless
the University if any legal action of any nature results from any such violation.

 

		8.7	Assignment. This Agreement may not be assigned or transferred (either directly or indirectly, by
operation of law or otherwise, including by way of a merger, acquisition or other sale event) without the prior written consent of the
other party, which consent will not be unreasonably withheld. This Agreement is binding upon and will inure to each party's respective
permitted successors in interest.

 

		8.8	Severability. If any provision of this Agreement is held void or unenforceable, the remaining provisions
will nevertheless be effective, the intent being to effectuate this Agreement to the fullest extent possible.

 

		8.9	Independent Contractors. The parties are deemed independent contractors and may not bind the other,
except as provided for herein or authorized in writing by the other party.

 

		9.10	Force Majeure. If either party hereto shall be delayed or hindered in, or prevented from, the performance
of any act required hereunder for any reason beyond such party’s direct control, including but not limited to, strike, lockouts,
labor troubles, governmental or judicial actions or orders, riots, insurrections, war, acts of God, inclement weather, epidemics, pandemics,
or other reason beyond the party’s control (a “Disability”) then such party’s performance shall be excused for
the period of the Disability. Any timelines affected by a Disability shall be extended for a period equal to the delay and any affected
Budget shall be adjusted to account for cost increases or decreases resulting from the Disability.

 

		9.11	Public Records. When fully executed, this Agreement itself cannot be Confidential Information per
the Arizona Public Records Law, Arizona Revised Statutes 39-121 and 41-1350

 

		9.10	Electronic Signatures. This Agreement may be executed in any number of counterparts, each of which
shall be an original and all of which together shall constitute one and the same document, and is binding on all Parties notwithstanding
that each of the Parties may have signed different counterparts. Facsimiles or scanned copies of signatures or electronic images of signatures
shall be considered original signature unless prohibited by applicable law.

 

 

(signatures next page)

 

 

 

    	 	5	 

     

    

 

IN WITNESS THEREOF, the parties execute this
Agreement as of the day and year written below.

 

	SPONSOR	 	The Arizona Board of Regents
	 	 	on behalf of The University
of Arizona
	 	 	 
	 	 	 
	By: /s/ Steve N. Slilaty                             	 	By: /s/ Elisha Johnson, JD                                
	 	 	 
	Name: Steve N. Slilaty, Ph.D.                  	 	Name:
Elisha Johnson, JD
	 	 	 
	Title: CEO                                                   	 	Title:
Director, Clinical Trials and Contracting
	 	 	 
	Date: 2/2/22                                                	 	Date: 2/18/22                                                       
	 	 	 
	 	 	Read and Acknowledged
	 	 	 
	 	 	 
	 	 	__________________________________
	 	 	/s/ Gregory Thatcher, PhD

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	6	 

     

    

 

EXHIBIT A

 

Research Project -- Statement of Work 

 

Dated November 15, 2021

For reference only 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	7	 

     

    

 

EXHIBIT B

 

Payment Schedule and Cost

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	8	 

     

    

 

Exhibit C

Additional Binding Terms

If checked, the following terms apply to the Agreement:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]